efaroxan has been researched along with Diabetes Mellitus, Type 1 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, MF; Cheng, JT; Chou, MT; Chung, HH; Yang, TT | 1 |
| Abdel-Zaher, AO; Ahmed, IT; El-Koussi, AD | 1 |
2 other study(ies) available for efaroxan and Diabetes Mellitus, Type 1
| Article | Year |
|---|---|
Improvement of hyperphagia by activation of cerebral I(1)-imidazoline receptors in streptozotocin-induced diabetic mice.
Topics: Animals; Benzofurans; Cerebrum; Diabetes Mellitus, Type 1; Disease Models, Animal; Eating; Female; Humans; Hyperphagia; Hypothalamus; Imidazoles; Imidazoline Receptors; Male; Mice; Mice, Inbred BALB C; Neuropeptide Y; Oxazoles; Rilmenidine; Streptozocin | 2012 |
The potential antidiabetic activity of some alpha-2 adrenoceptor antagonists.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Aorta, Thoracic; Benzofurans; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hypoglycemic Agents; Imidazoles; In Vitro Techniques; Insulin; Male; Rabbits; Rats; Rats, Wistar; Vasodilation; Yohimbine | 2001 |